伯氨喹剂量与无并发症间日疟患者溶血风险:系统综述与个体患者数据Meta分析
该系统综述与个体患者数据Meta分析纳入18项研究共5462例来自15个国家的无并发症间日疟患者,评估不同伯氨喹方案溶血风险。主要结局为第14天血红蛋白下降超过25%且低于7 g/dL,各剂量组发生率均低(0-0.5%)。葡萄糖-6-磷酸脱氢酶(G6PD)活性≥30%者用0.25-0.5 mg/kg/日、G6PD活性≥70%者用0.25-1 mg/kg/日伯氨喹,溶血风险与未用伯氨喹者相似。
要点
- 18项研究5462例患者中,第14天血红蛋白下降>25%且<7 g/dL的发生率:未用伯氨喹组0.1%、低剂量组0%、中剂量组0.3%、高剂量组0.5%。
- G6PD活性≥30%者用0.25-0.5 mg/kg/日伯氨喹,溶血风险与未用伯氨喹者相似。
- G6PD活性≥70%者用0.25-1 mg/kg/日伯氨喹,溶血风险与未用伯氨喹者相似。
核心结论
- G6PD活性≥30%的患者使用0.25-0.5 mg/kg/日伯氨喹方案、G6PD活性≥70%的患者使用0.25-1 mg/kg/日方案,溶血风险与未用伯氨喹者相似,支持在这些剂量下安全使用伯氨喹根治。
研究设计与样本
- 系统综述与个体患者数据Meta分析,检索MEDLINE、Web of Science、Embase和Cochrane Central,纳入2000年1月1日至2023年6月8日发表的前瞻性临床研究。
- 纳入标准包括:至少28天主动随访、伯氨喹在裂殖体杀灭剂治疗3天内开始并每日多日给药(单用或与氯喹或四种青蒿素联合疗法之一联用)、记录第0天血红蛋白或血细胞比容。
- 排除预防、预防性用药、重症疟疾或从医疗记录回顾性提取数据的研究;共纳入18项研究、5462例来自15个国家的患者。
主要发现
- 第14天血红蛋白下降超过25%且低于7 g/dL:未用伯氨喹组1208例中1例(0.1%),低剂量组(<0.375 mg/kg/日)893例中0例,中剂量组(0.375至<0.75 mg/kg/日)1464例中5例(0.3%),高剂量组(≥0.75 mg/kg/日)1269例中6例(0.5%)。
- 协变量调整后第2-3天平均血红蛋白变化:未用伯氨喹组-0.6 g/dL(95%CI -0.7至-0.5),低剂量组-0.7 g/dL(95%CI -0.8至-0.5),中剂量组-0.6 g/dL(95%CI -0.7至-0.4),高剂量组-0.5 g/dL(95%CI -0.7至-0.4)。
- 51例G6PD活性30%至<70%的患者中,调整后第2-3天平均血红蛋白浓度随G6PD活性降低而下降;该组中2例接受高剂量伯氨喹者出现血红蛋白下降超过25%且低于7 g/dL。
- 18项研究中17项偏倚风险低或不清楚。
关键数值与推荐
- G6PD活性≥30%的患者使用0.25-0.5 mg/kg/日伯氨喹方案,溶血风险与未用伯氨喹者相似。
- G6PD活性≥70%的患者使用0.25-1 mg/kg/日伯氨喹方案,溶血风险与未用伯氨喹者相似。
临床怎么用
- 作者结论支持G6PD活性≥30%者使用0.25-0.5 mg/kg/日伯氨喹、G6PD活性≥70%者使用0.25-1 mg/kg/日伯氨喹进行根治,溶血风险与未用伯氨喹者相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primaquine radical cure is used to treat dormant liver-stage parasites and prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We undertook a systematic review and individual patient data meta-analysis to investigate the haematological safety of different primaquine regimens for P vivax radical cure. METHODS: For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, if they included a treatment group with daily primaquine given over multiple days where primaquine was commenced within 3 days of schizontocidal treatment and was given alone or coadministered with chloroquine or one of four artemisinin-based combination therapies (ie, artemether-lumefantrine, artesunate-mefloquine, artesunate-amodiaquine, or dihydroartemisinin-piperaquine), and if they recorded haemoglobin or haematocrit concentrations on day 0. We excluded studies if they were on prevention, prophylaxis, or patients with severe malaria, or if data were extracted retrospectively from medical records outside of a planned trial. For the meta-analysis, we contacted the investigators of eligible trials to request individual patient data and we then pooled data that were made available by Aug 23, 2021. The main outcome was haemoglobin reduction of more than 25% to a concentration of less than 7 g/dL by day 14. Haemoglobin concentration changes between day 0 and days 2-3 and between day 0 and days 5-7 were assessed by mixed-effects linear regression for patients with glucose-6-phosphate dehydrogenase (G6PD) activity of (1) 30% or higher and (2) between 30% and less than 70%. The study was registered with PROSPERO, CRD42019154470 and CRD42022303680. FINDINGS: Of 226 identified studies, 18 studies with patient-level data from 5462 patients from 15 countries were included in the analysis. A haemoglobin reduction of more than 25% to a concentration of less than 7 g/dL occurred in one (0·1%) of 1208 patients treated without primaquine, none of 893 patients treated with a low daily dose of primaquine (<0·375 mg/kg per day), five (0·3%) of 1464 patients treated with an intermediate daily dose (0·375 mg/kg per day to <0·75 mg/kg per day), and six (0·5%) of 1269 patients treated with a high daily dose (≥0·75 mg/kg per day). The covariate-adjusted mean estimated haemoglobin changes at days 2-3 were -0·6 g/dL (95% CI -0·7 to -0·5), -0·7 g/dL (-0·8 to -0·5), -0·6 g/dL (-0·7 to -0·4), and -0·5 g/dL (-0·7 to -0·4), respectively. In 51 patients with G6PD activity between 30% and less than 70%, the adjusted mean haemoglobin concentration on days 2-3 decreased as G6PD activity decreased; two patients in this group who were treated with a high daily dose of primaquine had a reduction of more than 25% to a concentration of less than 7 g/dL. 17 of 18 included studies had a low or unclear risk of bias. INTERPRETATION: Treatment of patients with G6PD activity of 30% or higher with 0·25-0·5 mg/kg per day primaquine regimens and patients with G6PD activity of 70% or higher with 0·25-1 mg/kg per day regimens were associated with similar risks of haemolysis to those in patients treated without primaquine, supporting the safe use of primaquine radical cure at these doses. FUNDING: Australian National Health and Medical Research Council, Bill & Melinda Gates Foundation, and Medicines for Malaria Venture.
引用
- Rajasekhar M, Simpson JA, Ley B, et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2023. PMID: 37748497. doi:10.1016/S1473-3099(23)00431-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。